LB Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for LB Pharmaceuticals (LBRX).

Price Target Range — 5 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$54Upside to Avg. PT+36.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Canaccord Genuity	Sumant Kulkarni	Initiate	Buy	$65
Oct 6, 2026	Guggenheim	Delma Caiati	Initiate	Buy	$80
Oct 5, 2026	Roth Capital	Boobalan Pachaiyappan	Downgrade	Buy→Neutral	$37→$35
Oct 2, 2026	Needham	Ami Fadia	Initiate	Buy	$68
Aug 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$60
Aug 12, 2026	BMO Capital	Malcolm Hoffman	PT Raise	Outperform	$46→$54
Aug 3, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
Jul 21, 2026	BMO Capital	Malcolm Hoffman	Initiate	Outperform	$46
Jul 7, 2026	Wolfe Research	Rudy Li	Initiate	Outperform	$45
Apr 27, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Initiate	Buy	$45
Apr 10, 2026	Craig-Hallum	Adam Vogel	Initiate	Buy	$36
Mar 27, 2026	Stifel	Paul Matteis	PT Raise	Buy	$35→$40
Dec 11, 2025	Stifel	Paul Matteis	PT Raise	Buy	$27→$35
Oct 6, 2025	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$78
Oct 6, 2025	Stifel	Paul Matteis	Initiate	Buy	$27
Oct 6, 2025	Leerink Partners	Marc Goodman	Initiate	Outperform	$34

Analyst Ratings News

PRO
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.

Benzinga Newsdesk

PRO
Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

Roth Capital analyst Boobalan Pachaiyappan downgrades LB Pharmaceuticals (NASDAQ:LBRX) from Buy to Neutral and lowers the price target from $37 to $35.

Benzinga Newsdesk

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.

Avi Kapoor

PRO
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $68.

Benzinga Newsdesk

Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.

Avi Kapoor

LB Pharmaceuticals Inc

LB Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

PRO
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

PRO
Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

LB Pharmaceuticals Inc

LB Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

PROGuggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

PRORoth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRONeedham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

PRO
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

PRO
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

PRO
Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

PRO
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68